Capricor Therapeutics Investors Can Lead Class Action Lawsuit
Purchasers or acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025, and July 26, 2026, may have the opportunity to lead a class action lawsuit.
Investors who purchased or acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities and sustained substantial losses may have an opportunity to lead a class action lawsuit. The deadline to seek lead plaintiff status is September 28, 2026.
The lawsuit alleges that purchasers or acquirers may have been harmed by alleged misrepresentations concerning Capricor's business, operations, and/or insider information. This period covers December 17, 2025, through July 26, 2026.
Potential investment liabilities arose from alleged false or misleading statements and/or omissions of necessary corrections in Capricor's public disclosures. The court requires potential lead plaintiffs to meet certain criteria.
Capricor Therapeutics is a biotechnology company focused on developing treatments for cardiovascular diseases.